Rosamond W. Heart disease and stroke statistics-2008 update[J]. Circulation,2008,117:e25.
[2]
Kannel W B. Incidence and epidemiology of heart failure[J]. Heart Fail Rev, 2000,5:167.
[3]
Sliwa K, Damasceno A, Mayosi B M. Epidemiology and etiology of cardiomyopathy in africa[J]. Circulation, 2005,112:3577.
[4]
Douglas L Mann. Mechanisms and models in heart failure: a combinatorial approach[J]. Circulation, 1999,100:999.
[5]
Ashrafian H, Frenneaux M P, Opie L H. Metabolic mechanisms in heart failure[J]. Circulation, 2007,116:434.
[6]
Morrow D A, Givertz M M. Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease[J]. Circulation, 2005,112(21):3218.
[7]
Ashrafian H, Frenneaux M P, Opie L H. Metabolic mechanisms in heart failure[J]. Circulation, 2007,116(4):434.
[8]
Currie S, Smith G L. Enhanced phosphorylation of phospholamban and down regulation of sarco/endoplasmic reticulum Ca2+ ATPase type 2 (SERCA 2) in cardiac sarcoplasmic reticulum from rabbits with heart failure[J]. Cardiovasc Res, 1999,41(1):135.
[9]
Yano M, Ikeda Y, Matsuzaki M. Altered intracellular Ca2+ handling in heart failure[J]. J Clin Invest, 2005,115(3):556.
[10]
Stanley W C, Recchia F A, Lopaschuk G D. Myocardial substrate metabolism in the normal and failing heart[J]. Physiol Rev, 2005, 85(3):1093.
[11]
张子彬,Tsung O. Cheng,张玉传. 充血性心力衰竭学[M]. 第1版,北京:科学技术文献出版社,2000,3: 156, 551.
[12]
Neubauer S. The failing heart-an engine out of fuel[J]. N Engl J Med,2007,356:1140.
[13]
殷仁富,陈金明. 心脏能量学—代谢与治疗[M]. 上海:第二军医大学出版社, 2002:5.
[14]
房冬梅,冯美云. 运动对心肌组织能量代谢的影响[J]. 体育科研, 2002 (12):8 .
[15]
Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy[J]. Circulation,2008, 118(12):1250.
[16]
Fragasso G, Salerno A, Spoladore R, et al. Metabolic therapy of heart failure[J]. Curr Pharm Des, 2008,14(25):2582.
